Publications by authors named "Anne O Gang"

Background: There is limited knowledge of the long-term effects on the immune system after treatment for diffuse large B-cell lymphoma (DLBCL).

Methods: This study included DLBCL patients from the Danish Lymphoma Registry who obtained complete remission (CR) after (R)-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like immunochemotherapy. Each R CHOP-like treated patient was matched to five comparators from the Danish background population and furthermore compared to R CHOP-like treated patients.

View Article and Find Full Text PDF

Despite advances in treatment, approximately 15% of patients with diffuse large B-cell lymphoma (DLBCL) who achieve complete remission (CR) after first-line therapy will experience a relapse. However, there is no consensus on the optimal follow-up strategies for detecting relapse after achieving CR. This population-based study, based on the Danish Lymphoma Registry (LYFO), identified a total of 1634 patients diagnosed with DLBCL between 2010 and 2017, including 105 patients who achieved CR following first-line R-CHOP-like therapy and subsequently relapsed.

View Article and Find Full Text PDF

Introduction: Large B-cell lymphoma (LBCL) taxonomy has moved in the direction of a molecular classification, but further clinical experience is needed. We present high-risk gene mutations, which predict outcome in an exploratory study of a consecutive real-world cohort of patients with primary LBCL treated with R-CHOP or R-CHOP-like therapy.

Methods: The study was a Registry Study Research Project.

View Article and Find Full Text PDF

Introduction: Large B-cell lymphoma (LBCL) exhibits striking clinical and molecular heterogeneity. New approaches have emerged to explore tumor heterogeneity and classify LBCL into biological categories. Consequently, the informational requirements from diagnostic samples to provide the necessary information have increased, but the adequacy of single-site biopsies to provide such information is largely unknown.

View Article and Find Full Text PDF
Article Synopsis
  • High-dose chemotherapy can damage the gastrointestinal (GI) tract, leading to issues like mucositis and inflammation, with no effective preventive treatment available currently.
  • The study examines the impact of semaglutide, a GLP-1 receptor agonist, on reducing the severity of GI mucositis in lymphoma patients after high-dose chemotherapy and autologous stem cell transplantation.
  • This randomized, double-blind clinical trial involves 40 patients receiving either semaglutide or placebo, with assessments for GI mucositis severity, quality of life, and safety conducted weekly over a 10-week period.
View Article and Find Full Text PDF

Purpose: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.

Patients And Methods: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18-60 years with de novo DLBCL and age-adjusted IPI ≥2.

View Article and Find Full Text PDF
Article Synopsis
  • Advancements in lymphoma treatment have led to more long-term survivors who may face late effects like sexual dysfunction and testosterone deficiency, prompting this review's investigation into these issues among male survivors.* -
  • The review analyzed 20 articles, revealing a wide prevalence of low total testosterone (0%-50%) and compromised sexual health (23%-61%), with total testosterone levels being associated with sexual health outcomes.* -
  • Despite significant findings, the studies had high risk of bias, resulting in low confidence in the evidence; thus, further longitudinal studies are needed to improve understanding and establish standard procedures for assessing sexual health in these patients.*
View Article and Find Full Text PDF

To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.

View Article and Find Full Text PDF
Article Synopsis
  • Outcome data for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), especially beyond second-line therapy, is limited outside of clinical trials, making real-world context important.
  • A study in Denmark reviewed medical records of 3753 adults with DLBCL, focusing on 189 patients who received third-line treatment or beyond, with a median age of 71 years and various treatment options including supportive care and clinical trials.
  • Overall survival rates were low, with 2-year estimates at 25% for all patients and 49% for those receiving platinum-based salvage therapy, while certain factors like age, CNS involvement, and elevated LDH indicated poorer outcomes.
View Article and Find Full Text PDF

Introduction: Treatment of lymphoma can be associated with cognitive challenges, and some patients may fear development of dementia as long-term complication. Studies report a lower risk of dementia after cancer. Some believe this difference to be a protective mechanism of cancer, others believe it to be driven by bias.

View Article and Find Full Text PDF

In the current study, we report the prevalence of male testosterone deficiency in a cohort of 60 male long-term survivors of malignant lymphoma with normal total testosterone but in the lower part of the reference level. Testosterone deficiency was defined as subnormal concentrations of total testosterone or subnormal concentrations of calculated free testosterone. The aim was to clarify whether total testosterone was sufficient for identification of testosterone deficiency in male survivors of malignant lymphoma.

View Article and Find Full Text PDF

Introduction: Integration of molecular characterization of lymphomas in clinical diagnostics may improve subclassification and risk-stratification, and we implemented a next generation sequencing (NGS) analysis as part of routine diagnostic work-up of all mature B-cell non-Hodgkin's lymphoma (B-NHL). Here, we present data of mutational profiles with potential complementary diagnostic, prognostic, and predictive value detected in our consecutive non-selected cohort of B-NHL patients.

Methods: NGS results from 298 patients with both newly diagnosed and relapsed/refractory disease were included as a single center study.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, both regarding clinical presentation, response to treatment and outcome. Recently, subclassification of DLBCL based on mutational profile has been suggested, and next generation sequencing (NGS) analysis may be relevant as part of the diagnostic workflow. This will, however, often be based on analysis of one tumor biopsy.

View Article and Find Full Text PDF

Background: With improved survival in patients with lymphoma, long-term toxicity and quality of life (QoL), including sexual health, have become increasingly important.

Aim: We aimed to (1) determine the prevalence of erectile dysfunction (ED) in adult male lymphoma survivors; (2) determine whether testosterone deficiency, comorbidities, or lifestyle factors were associated; and (3) evaluate their impact on QoL.

Methods: A cross-sectional study including 172 male survivors of Hodgkin lymphoma or diffuse large B cell lymphoma diagnosed in adulthood between 2008 and 2018 was performed.

View Article and Find Full Text PDF

Objectives: Initial responses to coronavirus disease 2019 vaccination are impaired in patients with hematological malignancies. We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination.

Methods: In 407 hematological patients (45 myeloid, 362 lymphoid) and 98 matched controls, we measured immunoglobulin G (IgG) and neutralizing antibodies specific for the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline, 3 weeks, 2, 6, and 12 months, and interferon-γ release at 12 months.

View Article and Find Full Text PDF

Purpose: Many patients diagnosed with lymphoma are of working age. Cancer patients are known to have a higher risk of sick leave and disability pension, but this has only been delineated for certain subtypes of lymphoma. Therefore, this study aimed at investigating the overall risk of disability pension for all lymphoma subtypes and at quantifying return to work for patients with lymphoma in work before diagnosis.

View Article and Find Full Text PDF

Patients with hematological malignancies are prioritized for COVID-19 vaccine due to their high risk for severe SARS-CoV-2 infection-related disease and mortality. To understand T cell immunity, its long-term persistence, and its correlation with antibody response, we evaluated the BNT162b2 COVID-19 mRNA vaccine-specific immune response in chronic lymphocytic leukemia (CLL) and myeloid dysplastic syndrome (MDS) patients. Longitudinal analysis of CD8 T cells using DNA-barcoded peptide-MHC multimers covering the full SARS-CoV-2 Spike-protein (415 peptides) showed vaccine-specific T cell activation and persistence of memory T cells up to six months post-vaccination.

View Article and Find Full Text PDF

Chronic lymphocytic leukemia (CLL) patients with unmutated immunoglobulin heavy chain (IgHV) are at risk of early disease progression compared to patients with mutated IgHV. As a preventive strategy, we treated 19 previously untreated CLL patients with unmutated IgHV in a phase 1/2 trial (clinicaltrials.gov, NCT03939234) exploring the efficacy and toxicity of a therapeutic cancer vaccine containing peptides derived from programmed death ligand 1 (PD-L1) and ligand 2 (PD-L2), hoping to restore immunological control of the disease.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to understand the immune responses in COVID-19 patients, as current knowledge around disease severity is limited.
  • Researchers assessed immune reactions in 30 hospitalized patients using a whole-blood assay to measure cytokine responses and immune cell profiles.
  • Findings reveal that weakened innate immune responses upon hospitalization correlate with worse disease outcomes, offering a potential method for early risk assessment and patient management in COVID-19 cases.
View Article and Find Full Text PDF

Inactivating mutations in Bruton's tyrosine kinase () in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the mutation status in a real-world cohort of patients with non-Hodgkin lymphoma.

View Article and Find Full Text PDF
Article Synopsis
  • * Results show NHL patients had a higher risk of developing DM within the first year post-treatment, with the most significant risk ratio being 2.7, though the absolute risks were mostly clinically insignificant.
  • * For patients with preexisting DM, there was a temporary increase in the need for insulin treatment and a higher risk of cardiovascular diseases in the first year after chemotherapy, but overall, the increased risks were not considered
View Article and Find Full Text PDF

Diffuse large B-cell lymphoma is an aggressive disease occurring primarily in elderly patients. Despite high curative rates with doxorubicin-containing treatment, some elderly patients receive less intensive treatments, mainly due to advanced age, comorbidities, and concerns of cardiotoxicity from doxorubicin-containing regimens. We analyzed 1009 patients aged 75 years or older and 10,090 age- and sex-matched comparisons.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionrhh7c19qk9sg4iga2b1nfd6aaeghlkbb): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once